$0.12
+41.01%Price chart
Aug 17Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.10
From 52W high−73.45%
Volume13904.00
Market cap$1.39M
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataSep 18, 2026
Open
$0.10
From 52W high
−73.45%
Volume
13904.00
Market cap
$1.39M
ValuationView details →
P/E (Fwd)
1.3x
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
44.7
MomentumView details →
1D Return
+41.01%
YTD Return
+5.37%
SummaryUpdated Jun 1, 2026
Scilex Holding Company (NASDAQ:SCLX) is a biopharmaceutical company founded in 2016 and publicly traded since March 2021. Based in Palo Alto, California, the company operates as a subsidiary of Sorrento Therapeutics and focuses on developing and commercializing non-opioid pain management solutions. Scilex addresses the critical healthcare challenge of treating acute and chronic pain without contributing to the opioid crisis that has plagued the United States for decades.
Similar companies
Latest newsMore news →
DataMeds AI announced the pending transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings and HealthBridge Associates to consolidate intellectual properties and deliver the 'Health Lives Here' consumer app in partnership with NFL Alumni Health.34d agoScilex loan was substantially repaid to Oramed Pharmaceuticals.87d agoScilex Holding Company set June 15, 2026 as the payment date for its previously announced dividend of Semnur Pharmaceuticals common stock to holders of Scilex common stock and other eligible equity securities.108d ago